🇺🇸 FDA

Intelligence Platform

Patents

Browse 173 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10953046

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10946045

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10946044

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10933094

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10934550

Immunotherapy of cancer

Phio Pharmaceuticals Corp. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10935554

Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specifi

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10918666

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10894044

Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer

The Board of Regents of the University of Texas System · Granted Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10894063

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10835595

PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy

Inovio Pharmaceuticals, Inc. · Granted Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10835604

Biomaterials for combined radiotherapy and immunotherapy of cancer

Northwestern University · Granted Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10821163

Process for the production of a DNA vaccine for cancer immunotherapy

Vaximm AG · Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10815455

Salmonella-based vectors for cancer immunotherapy targeting Wilms' tumor gene WT1

Vaximm AG · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10799567

Yeast-based immunotherapy and type I interferon sensitivity

The Regents of the University of Colorado · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10722523

Chemoimmunotherapy for epithelial cancer

The Regents of the University of California · Granted Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10722537

Activation of resident memory T cells for cancer immunotherapy

Regents of the University of Minnesota · Granted Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10711312

Methods for immunotherapy-based treatment and assessment of cancer

The Regents of the University of California · Granted Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10695372

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10676530

Methods for treating allergy and enhancing allergen-specific immunotherapy by administerin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10653723

Processes for production of tumor infiltrating lymphocytes and uses of the same in immunot

Iovance Biotherapeutics, Inc. · Granted Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10646517

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10639330

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10537595

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10463697

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted